Trial Profile
Cytokines in the treatment of metastatic renal cell carcinoma (MRCC): intravenous interleukin and subcutaneous interferon-alpha versus subcutaneous interleukin and interferon-alpha for good prognosis patients [PERCY DUO]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Aldesleukin (Primary) ; Interferon alpha (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 15 Sep 2008 Primary endpoint 'overall survival' has not been met.
- 15 Sep 2008 Results published in Clinical Cancer Research.
- 01 Feb 2007 New trial record.